NIH researchers make progress toward Epstein-Barr virus (EBV) vaccine, with novel vaccine candidates that, in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers. Worldwide, EBV-associated cancers results in 140,000 deaths.

See the source article by following the link below:
NIH researchers make progress toward Epstein-Barr virus (EBV) vaccine, with novel vaccine candidates that, in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers. Worldwide, EBV-associated cancers results in 140,000 deaths.